Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Pomegranate-Based Drug May Stem Alzheimer’s, Parkinson’s

By Drug Discovery Trends Editor | August 22, 2014

Regular intake and regular consumption of pomegranate has many health benefits including prevention of neuro-inflammation related to dementia which slows down the progression of the disease. (Source: University of HUddersfield)The onset of Alzheimer’s disease can be slowed and some of its symptoms curbed by a natural compound that is found in pomegranate. Also, the painful inflammation that accompanies illnesses such as rheumatoid arthritis and Parkinson’s disease could be reduced, according to the findings of a two-year project headed by University of Huddersfield scientist Dr. Olumayokun Olajide, who specializes in the anti-inflammatory properties of natural products.
 
Now, a new phase of research can explore the development of drugs that will stem the development of dementias such as Alzheimer’s, which affects some 800,000 people in the UK, with 163,000 new cases a year being diagnosed. Globally, there are at least 44.4 million dementia sufferers, with the numbers expected to soar.
 
The key breakthrough by Olajide and his co-researchers is to demonstrate that punicalagin, which is a polyphenol– a form of chemical compound– found in pomegranate fruit, can inhibit inflammation in specialized brain cells known as micrologia. This inflammation leads to the destruction of more and more brain cells, making the condition of Alzheimer’s sufferers progressively worse.
 
There is still no cure for the disease, but the punicalagin in pomegranate could prevent it or slow down its development.
 
Olajide worked with co-researchers– including four Ph.D. students– in the University of Huddersfield’s Department of Pharmacy and with scientists at the University of Freiburg in Germany. The team used brain cells isolated from rats in order to test their findings. Now, the research is published in the latest edition of the journal Molecular Nutrition & Food Research and Olajide will start to disseminate his findings at academic conferences.
 
He is still working on the amounts of pomegranate that are required, in order to be effective.
 
“But we do know that regular intake and regular consumption of pomegranate has a lot of health benefits– including prevention of neuro-inflammation related to dementia,” he said, recommending juice products that are 100% pomegranate, meaning that approximately 3.4% will be punicalagin, the compound that slows down the progression of dementia.
 
Olajide stated that most of the anti-oxidant compounds are found in the outer skin of the pomegranate, not in the soft part of the fruit. And, he added, although this has yet to be scientifically evaluated, pomegranate will be useful in any condition for which inflammation– not just neuro-inflammation– is a factor, such as rheumatoid arthritis, Parkinson’s and cancer.
 
Olajide is also collaborating with his University of Huddersfield colleague, the organic chemist Dr. Karl Hemming. They will attempt to produce compound derivatives of punicalagin that could the basis of new, orally administered drugs that would treat neuro-inflammation.
 
He attributes this area of research to his upbringing. “African mothers normally treat sick children with natural substances such as herbs. My mum certainly used a lot of those substances. And then I went on to study pharmacology!”
 
Date: August 22, 2014
Source: University of Huddersfield
 

Filed Under: Drug Discovery

 

Related Articles Read More >

Recursion Pharmaceuticals Logo
Recursion’s Phase 3 FAP trial will count large-polyp removals as events under FDA-agreed design
Ball-and-stick model of the cancer drug imatinib
After six years in stealth, Humanitas bets on hybrid AI for drug discovery
NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE